Foresite Capital Management II’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-700,000
| Closed | -$4.03M | – | 9 |
|
|
2018
Q4 | $4.03M | Buy |
700,000
+200,000
| +40% | +$1.15M | 2.13% | 7 |
|
|
2018
Q3 | $6.78M | Sell |
500,000
-200,000
| -29% | -$2.71M | 2.51% | 7 |
|
|
2018
Q2 | $8.31M | Buy |
700,000
+300,000
| +75% | +$3.56M | 2.93% | 7 |
|
|
2018
Q1 | $4.49M | Buy |
+400,000
| New | +$4.49M | 1.49% | 7 |
|
|
2016
Q3 | – | Sell |
-1,054,864
| Closed | -$8.6M | – | 11 |
|
|
2016
Q2 | $8.6M | Sell |
1,054,864
-706,703
| -40% | -$5.76M | 5.88% | 7 |
|
|
2016
Q1 | $14.3M | Hold |
1,761,567
| – | – | 7.01% | 5 |
|
|
2015
Q4 | $21.2M | Buy |
1,761,567
+4,299
| +0.2% | +$51.8K | 7.12% | 3 |
|
|
2015
Q3 | $21M | Hold |
1,757,268
| – | – | 6.39% | 4 |
|
|
2015
Q2 | $32.2M | Buy |
+1,757,268
| New | +$32.2M | 11.3% | 2 |
|